Sol-Gel, Beimei sign deal for TWYNEO commercialisation
TWYNEO is claimed to be the first and only US Food and Drug Administration (FDA)-approved fixed-dose cream which combines tretinoin and benzoyl peroxide for treating acne vulgaris in
AstraZeneca has announced an ambitious target to deliver total revenue of $80bn by 2030, an increase from $45.8bn in 2023.